Differences in outcome by sex from recent cooperative group data/trials
| Cooperative group and y . | Length of therapy, y . | Sex-based difference in therapy length . | Outcome (5-y EFS) . | ||
|---|---|---|---|---|---|
| Girls . | Boys . | Statistically significant difference . | |||
| AIEOP-BFM 2000-200676 ,* | 2 from diagnosis | No | 59.1% ± 6.4% (HR) | 43.5% ± 5.3% (HR) | Not reported |
| 80.7% ± 1.7% (IR) | 74.9% ± 1.8% (IR) | ||||
| 92.3% ± 1.3% (SR) | 92.3% ± 1.3% (SR) | ||||
| COG 2000-20051 ,† | 2-3 from start IM | Yes | Hazard ratio (girls vs boys), 0.83 (95% CI, 0.77-0.90) | P < .001 | |
| DCOG 2004-201277 ,‡ | 2 from diagnosis | No | 89.2% ± 1.7% | 85.3% ± 1.7% | N/S in univariable analysis |
| DFCI 2005-201078 ,§ | 2 from EOI | No | 87% (95% CI, 83%-91%) | 86% (95% CI, 82%-89%) | N/S in multivariable analysis |
| MRC 2003-201179,80 ,‖ | 2-3 from start IM | Yes | Hazard ratio (girls vs boys), 0.78 (95% CI, 0.54-1.13) | N/S in multivariable analysis | |
| NOPHO 2008-201481 ,¶ | 2-2.5 from diagnosis | No | 84% ± 1% | 84% ± 2% | N/S in univariable analysis |
| SJCRH 2007-201782 ,# | 2.5 from diagnosis | No | 89.2% ± 4.9% | 87.6% ± 4.3% | N/S in univariable analysis |
| Cooperative group and y . | Length of therapy, y . | Sex-based difference in therapy length . | Outcome (5-y EFS) . | ||
|---|---|---|---|---|---|
| Girls . | Boys . | Statistically significant difference . | |||
| AIEOP-BFM 2000-200676 ,* | 2 from diagnosis | No | 59.1% ± 6.4% (HR) | 43.5% ± 5.3% (HR) | Not reported |
| 80.7% ± 1.7% (IR) | 74.9% ± 1.8% (IR) | ||||
| 92.3% ± 1.3% (SR) | 92.3% ± 1.3% (SR) | ||||
| COG 2000-20051 ,† | 2-3 from start IM | Yes | Hazard ratio (girls vs boys), 0.83 (95% CI, 0.77-0.90) | P < .001 | |
| DCOG 2004-201277 ,‡ | 2 from diagnosis | No | 89.2% ± 1.7% | 85.3% ± 1.7% | N/S in univariable analysis |
| DFCI 2005-201078 ,§ | 2 from EOI | No | 87% (95% CI, 83%-91%) | 86% (95% CI, 82%-89%) | N/S in multivariable analysis |
| MRC 2003-201179,80 ,‖ | 2-3 from start IM | Yes | Hazard ratio (girls vs boys), 0.78 (95% CI, 0.54-1.13) | N/S in multivariable analysis | |
| NOPHO 2008-201481 ,¶ | 2-2.5 from diagnosis | No | 84% ± 1% | 84% ± 2% | N/S in univariable analysis |
| SJCRH 2007-201782 ,# | 2.5 from diagnosis | No | 89.2% ± 4.9% | 87.6% ± 4.3% | N/S in univariable analysis |
Note. Different patient ages are included in these trials.
CI, confidence interval; EOI, end of induction; IM, interim maintenance; IR, intermediate risk; N/S, not significant.
B- and T-cell ALL (T-ALL) from AIEOP-BFM 2000 trial.
B- and T-ALL from trials AALL0232, AALL00P2, POG 9904, POG 9905, POG 9906, CCG-1991, and CCG-1961.
B- and T-ALL from DCOG ALL-10.
B-ALL only from DFCI 05-001.
B- and T-ALL from trial UK ALL 2003.
B- and T-ALL from NOPHO ALL-2008.
B- and T-ALL from St Jude Total Therapy XVI.